Clinical StudyTransarterial Chemoembolization with Irinotecan Beads in the Treatment of Colorectal Liver Metastases: Systematic Review
Section snippets
Literature Search Strategy
A systematic review was conducted by two authors (A.J.R. and V.L.). The following electronic databases were searched: Medline (1950–2012), Embase (1974–2012), the Cochrane controlled trials register, and the science citation index. Combinations of Medical Subject Headings as well as key words including the following were searched: “liver metastases,” “colorectal cancer,” “chemoembolization,” “drug-eluting beads,” “DEBIRI,” and “irinotecan.” The literature search was not restricted by language
Results
The search strategy is depicted in the Figure. The publication by Morise et al (11) had only four patients with incomplete follow-up data and was therefore excluded from analysis. After exclusion of dual publications (10, 12, 13, 14, 15, 16, 17), there were six studies included in the review (Table 1) (14, 15, 17, 18, 19, 20). The inclusion and exclusion criteria for treatment, along with the use of previous systemic chemotherapy, are noted in Table 1. With the exception of one study (18), all
Discussion
Surgical resection of CRLM remains the most efficacious treatment, with 5-year survival rates ranging from 29% to 70% (22, 23). However, surgical resection is possible in only approximately 25% of patients. Even in patients who have undergone resection, the recurrence rate can be as high as 75% (24). Therefore, there remains a need for palliative treatments and therapies that can downstage disease to the extent of resectability.
The results of the present systematic review suggest that DEBIRI
References (35)
- et al.
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases
J Gastrointest Surg
(2006) - et al.
Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study
HPB
(2010) - et al.
Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial
J Gastrointest Surg
(2012) - et al.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eur J Cancer
(2009) - et al.
Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases
J Control Release
(2006) - et al.
Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases
Gastroenterol Clin Biol
(2006) - et al.
Liver-directed therapies: does it make sense in the current therapeutic strategy for patients with confined liver colorectal metastases?
Clin Colorectal Cancer
(2012) - et al.
Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium
Int J Radiat Oncol Biol Phys
(2007) - et al.
Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations
J Vasc Interv Radiol
(2006) - Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;...
New paradigm in the management of liver-only metastases from colorectal cancer
Gastrointest Cancer Res
Epidemiology and management of liver metastases from colorectal cancer
Ann Surg
Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis
J Clin Oncol
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
J Clin Oncol
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
N Engl J Med
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
J Clin Oncol
Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma
Hepatology
Cited by (67)
ACR Appropriateness Criteria® Management of Liver Cancer: 2022 Update
2022, Journal of the American College of RadiologyMicrowave ablation combined with lipiodol-microsphere mixed or conventional transarterial chemoembolization for the treatment of colorectal liver metastases: A retrospective study
2022, Clinics and Research in Hepatology and GastroenterologyLocoregional approaches to colorectal liver metastasis – intra-arterial
2022, Contemporary Management of Metastatic Colorectal Cancer: A Precision Medicine ApproachTranscatheter Embolization of Liver Metastases
2020, Image-Guided Interventions: Expert Radiology Series, Third EditionChemoembolization in Conjunction with Bevacizumab: Preliminary Results
2018, Journal of Vascular and Interventional Radiology
None of the authors have identified a conflict of interest.